PROFESSIONAL EXPERIENCE
Industry Consultant
2013-present
Industry consultant providing providing scientific, regulatory and operational expertise. Examples of the types of projects for which I have been retained are listed below in no particular order:
- Worked with three different oncology companies to design the toxicology study packages necessary to support their INDA, and then in the preparation of the INDA’s, which were successfully submitted. (2013 through 2018). Currently working on my fourth INDA in the oncology space.
- Worked closely with a company that was developing a combination drug product to closely monitor ongoing technical work at a CRO, when possible cross contamination of toxicokinetic bioanalysis samples was a concern. (2018, 2019)
- Managed the toxicological testing program for the development of an orphan disease therapy for a small start-up company. (2016-2018)
- Prepared an extensive toxicology summary from literature sources on a novel use of a trace metal and then used it to prepare Module 2.4 through 2.7 of the CTD for a 505(b)(2) application (2017-2019)
- Sat on the project team for a small startup company looking to develop novel inflammatory bowel disease and have been responsible for the toxicology program Responsible for the toxicology program and the preparation of the Modules 2.6 and 2.7 CTD for INDA submission. (2017-2018)
- Performed due diligence in the review of six different molecules as potential in-license candidates (2017)
- Advised three different toxicology CRO on operations and strategy development (2013 to 2017), and chaired the Scientific Advisory Board of a small start-up CRO (2015-2017)
- Prepared a request for categorical exemption from completing an NDA Environmental Impact Statement (2013 to 2014)
- Performed a safety assessment review and prepared a whitepaper on the toxicity and risk associated with an unintended formulation additive in a drug delivery device (2015)
- Performed a gap analysis on the necessary steps that would be required to import a new sun screen preparation in to the U.S. (2015)
- Prepared a GRAS notification that covered a new use for an established food additive (2015 to 2016)
- Revised a set of precut labels to make them compliant with modern label guidelines and the Pregnancy and Lactation Labelling Rule (2018)
WIL Research Co., Ashland, OH (now part of Charles River Laboratories); held varied positions of increasing responsibility from 1990-2013 (retired)
Details associated with each position are summarized in the following sections. Some highlights from my tenure there include;
- Invigorated a General Toxicology Division; when I arrived, the division had 20 employees. When I moved on to assume higher management functions, the Division had over 300 employees and accounted for 55% of the Ashland site’s revenue.
- Member of the senior management team that took WIL independent from the Great Lakes Chemical Corporation in 2004.
- Led project teams that designed 300,000 sf of state of the art vivarium space, which included many (for the time) innovations; such as exercise areas for canines, and direct to report GLP complaint electronic temperature and humidity monitoring.
- Upgraded the intravenous infusion and surgical capability
- Upgraded cardiovascular capabilities and initiated the safety pharmacology program. This included developing the only program in the United Stated designed to address the EPA Clean Air Act requirements for determining the cardiac sensitization potential of Halon replacements.
- Served as study director on over 300 general toxicology studies, working on a variety of programs for products that were marketed; i.e., drugs, biologics, as well as food additives and pesticides. Experience with everything from an OTC Capsaicin dermal cream to stem cells developed for a neurological disease.
10/20/2010 -2/28/2013 Chief Scientific Officer for worldwide operations
As Chief Scientific Officer (member of the Corporate Executive Committee) of the WIL Research Company, provided global scientific counseling to the leaders of each operating subsidiary, the CEO and Chairman of WIL Research Company, and to the Company’s Executive Management Committee. Identified potential acquisition targets and provided appropriate due diligence support. Identified potential new service offerings for the company. Initiated a program to review the methodologies used at the company’s different locations and to assess these for strengths and weakness. Developed a seminar series so that the different sites were kept appraised of each other’s new technical developments.
12/06/08 – 10/20/10 Vice President and Chief Scientific Officer for WIL Research U.S.
Worked with the Chief Operating Officer to provide senior level leadership. Provided overall scientific and managerial leadership to the following departments: Analytical Chemistry/ADME, General Toxicology, Pathology, Safety Pharmacology, Study Analysis and Reporting, Surgery and Experimental Medicine, and Veterinary Services. Responsibilities included training and mentorship for direct reports. Developed departmental structures that were not over complicated and fostered growth. Developed plans for assessing the market place and new service offerings. Delegated and tracked acquisition, validation and marketing of new services. Worked with the business development group in developing a new company web-site. Reviewed reports, and provided scientific and technical advice. Reviewed and approved PAR and CAR’s. Promoted publication and professional society involvement.
11/08/97 - 12/05/08 Director, Toxicology Division
Overall managerial and technical responsibilities for the operation of the General Toxicology, Inhalation Toxicology, and Safety Pharmacology Departments. Direct reports included Director, Inhalation Toxicology, Director, Safety Pharmacology and Cardiovascular Sciences, Head of the Surgery and Experimental Medicine, Associate Director, General Toxicology and Assistant Director (Head of Juvenile Toxicology). Kept abreast of changes in guidelines, regulations and/or technology that impacted the business climate in which the Division operated. Reviewed and approved reports, protocols and SOPs. Responsible for the development and implementation of systems to increase efficiency and/or quality. Served as company representative at official functions.
12/15/95 - 11/07/97 Senior Toxicologist, Toxicology
Served as study director on subchronic, chronic, carcinogenicity (both EPA and FDA guidelines) metabolism/PK and neuro-toxicology studies. This included business development, client interactions, protocol generation, study monitoring, data interpretation, reporting and pricing. Took on special technical, management or marketing tasks. Reviewed reports, protocols and SOPs. Independent of study related activities, provided consultative services to clients on drug development projects and problems concerning chemical toxicity. Assisted clients in developing the necessary study packages to support clinical testing, and/or product registration.
09/24/90 - 07/11/95 Associate Director, Toxicology
Directed managerial and scientific responsibilities for the operations of the General Toxicology and Analytical Chemistry departments. Responsible for the development of new methodologies, such as continuous infusion studies, cardiac sensitization studies and inhalation studies in the dog. Served as study director on subchronic, chronic, carcinogenicity (both EPA and FDA guidelines) studies which included business development, client interactions, protocol generation, study monitoring, data interpretation, reporting and pricing. Oversaw the activities of other study directors. Assisted in the design of new facilities. Served on industry panels and other trade groups, and represented clients before various Federal agencies (FDA, EPA). Assisted several clients in developing the necessary study packages to support clinical testing, and/or product registration. Proactive in updating, developing and implementing employee safety programs.
Midwest Research Institute Kansas City, MO
07/12/95 - 12/14/95 Section Manager
Responsible for technical and administrative management of the Toxicology and Metabolism Section, including project staffing, staff management, technical planning, training, budgeting and document preparation. Principal investigator on MRI's contract with the National Cancer Institute to conduct preclinical toxicology studies of candidate anticancer and anti-HIV agents. I resigned from this position due to philosophical differences.
Searle R & D, U.S. Product Safety Skokie, IL 60077
1986 – 1990 Group Leader, Toxicology
1983 - 1986 Manager, Experimental and Acute Toxicology
1980 - 1983 Research Investigator
Last position involved the management and/or coordination of the activities of the General Toxicology Group, (3 Group Leaders, 4 Supervisors and 13 technical level personnel). Specific responsibilities included reviewing protocols and procedures for technical appropriateness, designing special mechanistic studies, scheduling and budgeting responsibilities. Served as study director, as described by the Good Laboratory Practices Act, on assigned preclinical safety studies which included protocol generation, study scheduling and report preparation. Authored over 100 safety studies, including several pivotal chronic studies required to support INDs and NDAs. Chaired the R & D Health Effects Committee. Served as resource person and coordinator for toxicity issues relating to industrial health and/or worker safety, which included preparation of opinions and review of SDS's. Initiated and oversaw the development or adoption of new testing protocols, particularly in the area of immunotoxicity, for supporting product applications and selection of drug candidates for development. Participated on both development and research project teams. This included designing and coordinating the toxicology study packages for product registration. Provided toxicological and scientific expertise in the following types of activities: preparation of toxicology summaries for submission to regulatory agencies, verbal presentations to company consultants on company products, regulatory bodies, and scientific conferences concerning safety data. Reviewed (toxicology) data packages on compounds considered for possible in-license. Supervised literature searches and summaries. Managed the Experimental Toxicology Laboratory, a "special projects" unit designed to primarily investigate toxicological issues outside the scope of traditional safety studies; designed and conducted experiments investigating mechanisms of toxicity involving the liver, thyroid, testes, kidney and heart. Organized and managed a small toxicology discussion series; scheduled times and assigned topics to participants. These discussions serve as a continuing education forum and also kept the senior staff abreast of current topics of concern. In addition, organized and coordinated an in-house course on clinical chemistry and hematology. Served on the Institutional Animal Care and Use Committee.
Formal Education
1977 PhD, Pharmacology
Department of Medical Pharmacology University of Illinois at the Medical Center Chicago, IL
Thesis Title: Ethanol-Drug Interactions in Isolated Hepatocytes
Thesis Advisor: Dr. Martin A Schulman (deceased)
1972 BS, Chemistry
Allegheny College Meadville, PA
Senior Project: Bioassay of Serotonin in Cerebral Spinal Fluid
Advisor: Herbert Rhinesmith (deceased)
Academic Experience
1993 - 2002 Adjunct Faculty, Ashland University,
Assisted in the development and lecturing in an undergraduate class in Toxicology.
1977 - 1980 Research Associate, Vanderbilt University Medical School Center in Environmental Toxicology
This was primarily a research position (post-doctoral position) but did involve some teaching responsibilities (approx. 10% of time devoted to lecturing in biochemistry and toxicology). Designed and executed a project investigating the relationship between carbon disulfide metabolism and toxicity that resulted in several manuscripts and identified novel route of xenobiotic metabolism.
Postdoctoral Advisor; Robert A Neal (deceased)
1972 - 1977 PHS Doctoral Trainee, University of Illinois Medical Center (Chicago), Department of Medical Pharmacology
Assisted in setting-up and teaching pharmacology laboratory sessions to medical students. Helped to grade examinations.
1971 - 1972 Undergraduate Teaching Assistant Allegheny College, Department of Chemistry
Certification
Diplomate, American Board of Toxicology; 1981 Recertification in 1986, 1991, 1996, 2001, 2006, 2011, 2016
Continuing Education
SOT Continuing Education Course on Mechanistic Understanding and Quantitative Risk Assessment in Immunotoxicology, 2018
ACT Continuing Education Course on the Common Technical Document for Regulatory Submission; Best Practices for Predation and Review, 2018
ACT Continuing Education Course on the Safety Evaluation of Vaccines, 2018 SOT Continuing Education Course on CRISPR/CAS 9 for Toxicologists, 2018
SOT Continuing Education Course on Evaluation of Leachable Substance from Materials with Applications in Foods and Pharmaceuticals, 2018
SOT Continuing Education Course on Assessment of Peri and Prepubertal Developmental and Reproductive Toxicity, 2018
ACT Continuing Education Course on Hematology and Immunotoxicity Assessment: Essential Principals and Emerging Modalities, 2017
SOT Continuing Education Course on Read-Across: Case Studies, New Techniques, and Guidelines for Practical Application, 2017
SOT Continuing Education Course on Technologies and Applications of Stem Cells for Use in Toxicology, 2017
SOT Continuing Education Course on Molecular Imaging for Toxicologists, 2017
SOT Continuing Education Course on Contribution of Mitochondria to Drug-Induced Organ Toxicities, 2016
Sot Continuing Education Course on Approaches to Investigate and Assess Risks Associated with Drug-Induced Liver Injury (DILI), 2016
ACT Continuing Education Course on Selection and Use of Non-Rodent Species for Nonclinical Safety Assessment - Benefits, Pitfalls and Caveats, 2015
ACT Continuing Education Course on Fundamentals of Translational Neuroscience in Toxicological Pathology: Optimizing the Value of Animal Data for Human Risk Assessment, 2015
SOT Continuing Education Course: Skeletal System Endocrinology and Toxicology, 2015
SPS Continuing Education Course: Cardiac Electrophysiology: The Biophysics of Ion Channels for the Safety Pharmacologist, 2014
ACT Continuing Education Course: Regulatory Toxicology –the FDA and Beyond, 2014
ACT Continuing Education Course: Toxicology and Pathology of the Respiratory System, 2014
SOT Continuing Education Course: Nonclinical Animal Models Enabling Biopharmaceutical Advances in Translational Medicine, 2014
ACT Continuing Education Course: Inflammatory Biomarkers, 2013
SOT Continuing Education Course: Tools and Technologies in Translational Toxicology, 2013
ACT Continuing Education Course: Understanding Statistics in Toxicological Research & Drug Development, 2012.
SPS Continuing Education Course: Improving Human Translation of Safety Pharmacology Models: Practical Applications of Advanced Tissue and Organ Engineering, 2012
SPS Continuing Education Course: Safety Biomarkers – What Every Safety Pharmacologist Should Know, 2012
SOT Continuing Education Sunrise Course: Alternative In Vitro Toxicology Testing for the 21st Century, 2012
SOT Continuing Education Course: Stem Cells in Toxicology, 2012
SOT Continuing Education Course: MicroRNAs in Biology and Toxicology, 2012
Cutting-Edge Imaging Technologies and Strategies in Preclinical Small Animal Research, 2012, Ann Arbor, MI
ISSX Short Course, Animal Models and Predictions of Drug Clearance and Dynamics; Are we Making Any Progress? Atlanta, GA, 2011
ACT Continuing Education Course: Introduction to Translational Imaging in Nonclinical Safety Assessment: A Technology and Applications Perspective, 2011
Applied Pharmaceutical Toxicology Continuing Education Course: Dedicated to Reducing Safety- Related Attrition, South San Francisco, CA, 2011
SOT Continuing Education Course: Technologies and Tools for Toxicity Testing in the 21st Century, 2010
SOT Continuing Education Course: Immunology for Toxicologists, 2009
SOT Continuing Education Course: Free Radicals for Toxicologists – From the Basics to Inflammation and Disease, 2009
SOT Continuing Education Course: The Use of Transgenic Animal Technology in Toxicologic Research, 2008
SOT Continuing Education Course: Nanotoxicology, The Science of Developing a Safe Technology, 2008
ACT Continuing Education Course: From Bench to Bedside: The Absolute Essentials of Preventative Vaccine Development, 2008
ACT Continuing Education Course: Anti-cancer Drug Development Overview: Advancing Our Understanding of Targeted Approaches to Anti-Cancer therapies, 2008
SOT Continuing Education Course: Rodent Imaging for the Toxicologist, 2007
ISSX Short Course: P450-dependent Metabolism in Extrahepatic tissue: Implications for Drug Disposition and Toxicology, 2007
ISSX Short Course: Metabolism based Neurotoxicity by Xenobiotics: Mechanism and Biomarkers, 2007
SPS Continuing Education: Advanced Topics in Cardiovascular Assessment, 2006
ACT Continuing Education Course: Basic Principles of Photosafety Testing and Regulatory Issues, 2006
SOT Continuing Education Course: Clinical Pathology-The Granddaddy of Biomarkers, 2005
SOT Continuing Education Course: International Harmonization of Technical Requirements for Conducting Non-clinical Safety Studies of Human Pharmaceuticals, 2005
ACT Continuing Education Course: Assessment of Mitochondrial Function in Disease and Drug-Induced Toxicity, 2005
SOT Continuing Education Course: Metabonomics Technology in Safety Assessment, 2004
ACT Continuing Education Course: Genetic Toxicology, Principles, Practices and Emerging Challenges, 2004
SOT Continuing Education Course: Genomics and Proteomics Array Formats, 2003
ACT Continuing Education Course: Toxicology Testing for Preventive Vaccine Development, 2003
SOT Continuing Education Course: Strategies and Issues in non-Clinical Development of Intravenous Infusion Drug Products, 2002
ACT Continuing Education Course: Biocompatibility and Regulatory Requirements for Medical Devices, 2002
ACT Continuing Education Course: Metabolites in Safety Testing, 2002
ACT Continuing Education Course on Practical Approaches to Applying Immunotoxicity Guidelines to Safety Assessment, 2001
SOT Continuing Education Course: Toxicokinetic and Physiologically-Based Toxicokinetics in Toxicology and Risk Assessment, 2000
SOT Continuing Education Course: Prediction of Human Toxicity and Metabolic Fate of Drugs using In Vitro systems, 2000
SOT Continuing Education Course; Genomic Technologies and New Screening strategies for Toxicology, 1999
ACT Continuing Education Course: Safety Assessment of Biotechnology Products, 1999
ISSX Continuing Education Course: LC/MS and LC/NMR Techniques in Drug Metabolism, 1999
SOT Continuing Education Course: Assessment of Cutaneous Toxicity, 1998
ACT Continuing Education Course: Experimental design for Large Animal Toxicity, 1998
ACT Continuing Education Course: Statistics and Carcinogenicity, 1997
SOT Continuing Education Course: Safety and Risk of New Food Technologies, 1997
SOT Continuing Education Course: Aptosis, 1996
ISSX Continuing Education Course: Genetic Therapy, 1996
ACT Continuing Education Course: Chronic Toxicity, 1996
SOT Continuing Education Course: Cytokines, 1995
MRC/SOT Short Course: Environmental Estrogens, 1995
SOT Continuing Education Course: Genetic Toxicology, 1994
SOT Continuing Education Course: Risk Assessment, 1993
MRC/SOT Short Course: Immunotoxicology, 1993
ACT Short Course: AIDs Models for Research, 1993
SOT Continuing Education Course: Implementing PBPK, 1992
SOT Continuing Education Course: Environmental Toxicology, 1991
MRC/SOT Short Course: Gastrointestinal Pathology, 1991
SOT Continuing Education Course: Advanced Hepatotoxicity, 1990
SOT Continuing Education Course: Respiratory Tract Toxicity, 1990
SOT Continuing Education Course: Advanced Renal Toxicology, 1989
SOT Continuing Education Course: Concepts in Molecular Biology, 1989
ISSX Continuing Education Course: Reactive Metabolite Chemistry for Toxicologists, 1987
SOT Continuing Education Course: Developmental Toxicology, 1986
SOT Continuing Education Course: Environmental Toxicology, 1986
IAPS Course: Toxicology of the Immune System, 1985
SOT Refresher Course: Hepatotoxicity, 1985
SOT Refresher Course: Carcinogenesis, 1984
Mid America Toxicology Course, 1984
SOT Refresher Course: Inhalation Toxicity, 1980
1981 Gordon Conference (Alcohol & Alcoholism), 1979
Professional Society Affiliations:
American Association for the Advancement of Science, associate member, 1974 - 1990
American College of Toxicology, full member in 1980
- Organized and chaired symposium on animal models for the 1990 meeting
- Chaired the ad hoc Student Affairs Committee, 1990 - 1991
- Placement Service Coordinator, 1990
- Chaired Poster Sessions at Annual Meeting, 1991 - 1993 Nominated and elected to Council, 1991 - 1994
- Chair of the Membership Committee, 1993 - 1994 Member, Membership Committee, 1994 - 1995
- Elected Vice-President, 1995 - 1996
- President Elect, Chair of Program Committee, 1996 - 1997 President, 1997 - 1998
- Past President, Chair of Nominating and Outreach Committees, 1998 - 1999
American Society for Pharmacology and Experimental Therapeutics (A.S.P.E.T.), full member in 1987. Emeritus member in 2019
- Member, Division of Drug Metabolism
- Member, Division of Toxicology
Greater Chicago Chapter - ASPET, 1988 - 1990
International Society for the Study of Xenobiotics, full member in 1986
International Society for Immunopharmacology, 1988 - 1993
Midwest Regional Chapter/Society of Toxicology, 1980-2010
- Councilor and Chairman of the Membership Committee, 1985 – 1987
- President-elect and Chairman of the Program Committee, 1987 - 1988
- President, 1988 - 1989
- Councilor and Chairman of the Education Committee, 1989 - 1990
Society of Toxicology, full member in 1985. Member of several specialty sections
- Nominated to the Nominating Committee, 1987
- Chaired platform session on biotransformation at national meeting, 1989
- Chaired poster session on acute/ocular toxicity at national meeting, 1990
- Chaired poster session on cardiotoxicity at national meeting, 2003
- Member of World Wide Web Committee, 2004 - 2006
Japanese Society of Toxicology, Associate Member, 2000 -2010
Awards and Honors:
- HHS. National Research Service Fellowship, 1978 – 1980
- Selected to Strathmore’s Who’s Who, 2003
- Selected to Kipling’s Whos’ Who in Leading Business Professionals, 2008
Other Professional Activities:
- Member of the Industrial Biotechnology Association's subcommittee in charge of developing guidelines for the preclinical testing of novel products produced by biotechnology (1984 - 1986).
- Regular attendee (1980 - 1990) at the Drug Safety Subsection Meetings (Western Region) of the Pharmaceutical Manufacturing Association, the Toxicology Forum and the Toxicology Round Table .
- Representative on the Brominated Fire Retardants Industry Panel, 1990 - 1992.
- Served on the ECETOC Expert Technical Committee for developing a technical monograph on the assessment of solvent related cardiac sensitization (published in 2009).
Peer reviewer for:
- Toxicology and Applied Pharmacology Journal of Applied Toxicology
- Research Communications in Chemical Pathology and Pharmacology
- Food and Chemical Toxicology
- Journal of Pharmacology and Experimental Therapeutics J. American College of Toxicology
- Molecular Pharmacology
- In Vitro Toxicology
Appointed to the Editorial Boards:
- Toxicology Methods and Mechanisms, 2000 – 2004
- Fundamental and Applied Toxicology, 1990 - 1994
- Journal of Applied Toxicology, 1998 - 2000
Research Interests/Technical Skills:
- Food Safety
- Dermal Toxicity Assessment.
- In vivo toxicology study design and interpretation,
- Cardiovascular toxicity assessment (including safety pharmacology)
- Biochemical mechanisms of liver, kidney, adrenal, thyroid and testicular toxicity,
- Reproductive toxicity
- Immunotoxicity.
Patent:
Diol-metabolites of 7-phenyl-1,2,4-triazolo-(2,3-C)-pyrimidines-5-amines. Patent No. 4,866,063. September, 12, 1989.
- Co-discovered that the major metabolite of one of Searle’s lead compound retained pharmacological activity, but lacked the parent’s toxicity profile.
Management Training
- Great Lakes Chemical Course on Leadership, 2003
- American Management Association course, "Improving Managerial Skills of the New or Prospective Manager," 1990.
- Coates-Freeman seminars on collaboration in, and improving the quality of, decision making; 1989.
- Performance Management System training; 1987. In-house course (Searle) on techniques for the appropriate management of subordinates, and the setting and tracking of goals.
Publications
Book or Chapters:
Chengelis. C.P., Godin, C.S. Lessons From the Front Lines in The Study Director in Nonclinical Studies for Drugs, Chemicals, Pesticides and Devices. Brock, W. Editor. (John Wiley and Sons, Hoboken,NJ) pp. 505-518, 2014
Chengelis, C.P.; Gad, S.C. Human Pharmaceutical Products. In Regulatory Toxicology, 2nd ed.; Gad, S.C., Ed.; (Taylor and Francis: New York, NY) 2001; pp. 9 - 69.
Gleason, T.R.; Chengelis, C.P. The Ambulatory Model in Dog Multidose Infusion Toxicity Studies. In The Handbook Pre-clinical Continuous Intravenous Infusion, Healing, G.; Smith, D.; (Taylor and Francis: New York, NY) 2001; pp.148 - 159.
Chengelis, C.P.; Gad, S. Toxicokinetic Studies in Commercial Development of Agricultural and Industrial Chemical Products. In Product Safety Evaluation Handbook, 2nd ed.; Gad, S., Ed., Marcel Dekker, Inc.: New York, NY, 1999; pp. 639 - 686.
Acute Toxicity Testing: Perspectives and Horizons, 2nd ed.; Gad, S.C.; Chengelis, C.P. Telford Press: Calwell, NJ, 2nd ed.; Academic Press: San Diego, CA,1997.
Regulatory Toxicology, Chengelis, C.P; Gad, S.G.; Holson, J.F.; Ed., Raven Press: New York, NY, 1995.
Chengelis, C.P. Acute Toxicity Testing in Drug Safety Evaluation. In Safety Evaluation of Pharmaceuticals, (John Wiley & Sons, Inc.: New York, NY); pp. 130 – 175, 1994
Animal Models in Toxicology. Gad, S.C.; Chengelis, C.P., Ed.; Taylor and Francis: Boca Raton, FL, 1992; pp. 1 - 921.
Peer Reviewed Publications ,:
Evaluation of the chronic toxicity and carcinogenicity of perfluorohexanoic acid in Sprague-Dawley Rats. Klaunig JE, Shinohara M, Iwai H, Chengelis CP, Kirkpatrick JB, Wang Z, and Bruner RH Toxicol Pathol. 43(2):209-20, 2015
Thirteen week toxicity studies in rats related to the safety in use of taurine, a constituent of so- called energy drinks, Chengelis, C,P,. Beck, M, Kroes, R. and Renwick A. G. Prepared for submission to Food and Chemical Toxicology 2013 (never submitted by the Sponsor)
Evaluation of propofol containing 2% benzyl alcohol preservative in cats, Taylor PM, Chengelis CP, Miller WR, Parker GA, Gleason TR, Cozzi E., J Feline Med Surg. 2012 Aug;14(8):516-26.
A 13-week dietary toxicity study in rats of a Napin-rich canola protein isolate. Mejia, L.A., Korgaonkar, C.K., Schweizer, M., Chengelis, C.P., Novilla, M., Ziemer, E., Williamson-Huges, P.S., Grabiel, R., Empie, M. Regulatory Toxicology and Pharmacology 55, 394-402, 2009,
Comparison of the toxicokinetic behavior of perfluorohexanoic acid (PFHxA) and nonafluorobutane-1-sulfonic acid (PFBS) in cynomolgus monkeys and rats. Chengelis CP, Kirkpatrick JB, Myers NR, Shinohara M, Stetson PL, Sved DW. Reprod Toxicol. 27:400-6., 2009
A 90-day repeated dose oral (gavage) toxicity Study of perfluorohexanoic acid (PFHxA) in rats (with functional observational battery and motor activity determinations) Chengelis, C.P., Kirkpatrick, J.A., Radovsky, A., and Shinohara, M. Reproductive Toxicology 27, 342-351, 2009
A 13-Week Sub-Chronic Dietary Toxicity Study of a Cruciferin-Rich Canola Protein Isolate in Rats, Mejia, L.A., Korgaonkar, C.K., Schweizer, M., Chengelis, C.P., Marit, G., Ziemer, E., Grabiel, R., Empie, M. Food and Chemical Toxicology 47, 2645-2654, 2009.
28-Day Oral (gavage) Toxicity Studies of Green Tea Catechins Prepared for Beverages in Rats, Chengelis, C.P., Kirkpatrick, J.B., Regan, K.S., Radovsky, A.E., Beck, M.J., Morita, O., Tamaki, Y., Suzuki, H. Food and Chemical Toxicology 46, 978-989, 2008.
Oral Administration of Dextromethorphan does not Produce Neuronal Vacuolation in the Rat Brain, Carliss, R.D., Radovsky, A., Chengelis, C.P., O’Neill, T.P., Shuey, D.L. NeuroToxicology 28, 813-818, 2007.
A 28-day Oral (dietary) Toxicity Study of Sucromalt in Sprague-Dawley Rats, Eapen, A.K., Chengelis, C.P., Jordan, N.P., Baumgartner, R.E., Zheng, G., and Carlson, T. Food and Chemical Toxicology 45, 2304-2311, 2007.
Different Species Require Different Correction Factors for the QT Interval, Soloviev, M.V., Hamlin, R.L., Barrett, R.M., Chengelis, C.P. and Schaefer, G.J. Cardiovascular Toxicology 145- 157, 2006.
A Chronic Dietary Toxicity Study of DAG (diacylglycerol) in Beagle dogs, Chengelis, C.P., Kirkpatrick, J.B., Marit, G.B., Morita, O., Tamaki, Y., Suzuki, H. Food and Chemical Toxicology 44(1) 81-97, 2006.
A 24-Month Dietary Carcinogenicity Study of DAG in Mice, Chengelis, C.P., Kirkpatrick, J.B., Bruner, R.H., Freshwater, L., Morita, O., Tamaki, Y., Suzuki, H. Food and Chemical Toxicology 44(1), 122-137, 2006.
A 24-Month Dietary Carcinogenicity Study of DAG (Diacylglycerol) in Rats, Chengelis, C.P., Kirkpatrick, J.B., Bruner, R.H., Freshwater, L., Morita, O., Tamaki, Y., Suzuki, H. Food and Chemical Toxicology 44, 98-121, 2005.
A 24-Hour Continuous Infusion Study of Bivalirudin in the Rat, Gleason, T.G., Chengelis, C.P., Jackson, C.B., Lindstrom, P. International Journal of Toxicology 22(3) 195-206, 2003.
In Vivo and In Vitro Induction of Cytochrome P450 Enzymes in Beagle Dogs, Graham, R.A., Downey, A., Mudra, D., Krueger, L., Carroll, K., Chengelis, C., Madan, A., and Parkinson, A. Drug Metabolism and Disposition 30(11) 1206-1213, 2002.
Promotional Activities of the non-genotoxic Carcinogen, Bemitradine, S. Gad, C. Chengelis, Y. Oshiro, D. Semler and S. Levin. Applied Toxicology 12(3) 157-164, 1992.
Age and Sex Related Changes in Epoxide Hydrolase, UDP-Glucuronosyl Transferase, Glutathione S-transferase, and PAPS-Sulfotransferase in Sprague- Dawley Rats. C. P. Chengelis. Xenobiotica 18:1225-1237, 1988.
Preliminary Studies on Bemitradine Induced Cardiotoxicity in Female Rats, C. P. Chengelis, S. Levin, E. Burton, S. Gad and G. Walsh. J. Am. Coll. Tox. 10, 511-524, 1991.
The Chronic Toxicity of Bemitradine in the Rat. C. P. Chengelis, S. Levin, E. Burton. J. Am. Coll. Tox. 10, 443-460, 1991.
The Effect of Molybdenum Depletion on Sulfite Oxidase, Cytochrome P-450, and Carbon Disulfide-Induced Hepatotoxicity in the Rat. C.P. Chengelis. J. Am. Coll. Tox. 10, 487-490, 1991.
Potential Applications for Species Not Commonly Used in General Toxicity Studies. C.P. Chengelis; based on invited lecture presented at the American College of Toxicology Meeting, October 30-November 1, 1989. J. Am. Coll. Tox. 9, 317-342, 1990.
The Effects of Chronic Ingestion of Spironolactone on Serum Thyrotropin and Thyroid Hormones in the Male Rat. D. E. Semler, C. P. Chengelis, and F. M. Radzialowski. Tox. Appl. Pharmcol. 98:263-268, 1989.
Age and Sex Related Changes in the Components of the Hepatic Microsomal Mixed Function Oxidase System in Sprague-Dawley Rats. C. P. Chengelis. Xenobiotica 18:1211-1224, 1988.
Paradoxical Effect of Cobaltous Chloride on Carbon Disulfide Induced Hepatotoxicity in Rats. C.P. Chengelis. Res. Commun. Chem. Path. Pharmacol. 61:83-96, 1988.
Chronic Toxicity of Bromovinyldeoxyuridine in Beagle Dogs. C. P. Chengelis, C. Port, and B. C. Dickie. Fund. Appl. Toxicol. 11:143-154, 1988.
Changes in Hepatic Glutathione Concentrations during Carbon Disulfide Induced Hepatotoxicity in the Rat. C. P. Chengelis. Res. Commun. Chem. Path. Pharmacol. 61:97-110, 1988.
Oxidative Metabolism of Carbon Disulfide by Isolated Rat Hepatocytes and Microsomes. C. P. Chengelis and R. A. Neal. Biochemical Pharmacol. 36:363-368, 1987.
Testicular Toxicity of a Novel, 1,4 Benzodiazopine. C. P. Chengelis, D. C. Dodd, and F. N. Kotsonis, Res. Commun. Chem. Path. Pharmacol. 51:23-36, 1986.
Changes in Thyroidal Function and Liver UDP-Glucuronosyl Transferase Activity in Rats Following Administration of a Novel Imidazole (SC-32711). C. P. Comer, C. P. Chengelis, S. Levin and F. N. Kotsonis, Toxicol. Appl. Pharmacol. 80:427-436, 1985.
Protection by Zinc Against Acetaminophen Induced Hepatotoxicity in Mice. C. P. Chengelis, D. C.Dodd, J. R. Means, and F. N. Kotsonis, Fund. Appl. Toxicol. 6:278-284, 1985.
Testicular Toxicity Induced by Oral Administration of SC-32855, a 1, 4-Benzodiazepine in the Dog. J. Means, C. P. Chengelis and V. Jasty, Res. Com. Chem. Path. Pharm. 37:317-320, 1982.
Synthesis of 14C and 35S Labelled Carbonyl Sulfide. C. P. Chengelis and R. A. Neal, J. Label. Comp. Radiopharm. 17:92-94, 1980.
Studies of Carbonyl Sulfide Toxicity. C. P. Chengelis and R. A. Neal, Toxicol. Appl. Pharmacol. 55:198-202, 1980.
Microsomal Metabolism of Diethyl Ether. C. P. Chengelis and R. A. Neal, Biochem. Pharmacol. 29:247-8, 1980.
Hepatic Carbonyl Sulfide Metabolism. C. P. Chengelis and R. A. Neal, Biochem. Biophysical Research, Communications, 90:993-999, 1979.
Abstract/Posters and Presentations:
Christopher P. Chengelis Book Review in International Journal of Toxicology, July/August 2015; vol. 34, 4: pp. 367-368. Metabolic Profiling: Disease and Xenobiotics (Volume 21 of Issues in Toxicology) USA M Grootveld ed
Trends in FDA GLP Enforcement: Impact on Data Quality and Study Integrity. Delivered to a meeting of the Applied Pharmaceutical Toxicology Conference (Sponsored by the Boston Society) , May 2011 in South San Francisco, CA
Draganov, D.; Johnson, T.L.; Knecht, C.; Godsey, J.; MacBride, M.; Sved, D.; Chengelis, C.P. Evaluation of drug disposition using transgenic animal models and quantitative whole body autoradiography. Annual Meeting of the Great Lakes Drug Metabolism Discussion Group, 2010.
Lambert, E.A., Hynick, J.R., Setser, J.J., Morris, J.D., Miller, W.R., Chengelis, C.P, 2008.The Development of an Ambulatory Continuous Infusion Method in the Nonhuman Primate, Poster Presentation at the American Association for Laboratory Animal Science, 2011.
Sloter, E.D., Nemec, M., Stump, D., Pritt, S., Beck, M., Gleason, T., Miller, W. and Holson, J. (2008) Ambulatory Continuous Intravenous Infusion Model for Pregnant Dutch Belted Rabbits, The Toxicologist, 355, Abstract 2301.
Chengelis, C, Kirkpatrick, J, Regan, K, Radovsky, A, Morita, O, Tamaki, Y, and Suzuki. H. 28-Day Oral (Gavage) Toxicity Studies in Rats of Green Tea Catechins Prepared for Beverages. 46th Annual Meeting of the Society of Toxicology, 2007.
Chengelis, C.P., Kirkpatrick, J.B., Lawrence, W.B., Morita, O., Tamaki, Y., Suzuki, H. 90-day Dietary Toxicity Study of Heated DAG Oil and Heated TG Oil in Rats. 44th Annual Meeting of the Society of Toxicology, 2005.
Coffee M., Haley S., Lawrence. W., and Chengelis C.P.. Historical Control Serum Clinical Chemistry Values for The Adult CRL:CD SD IGS BR RAT. Japanese Society of Toxicology, 2004.
Soloviev MV, Taylor MJ, Mertens JJWM, Schaefer GJ, Wilkinson GT, Edwards TR, Chengelis CP. Continuous evaluation of subcutaneous temperature in rats. 10th International Congress of Toxicology, 2004.
Kirkpatrick, J.B., Chengelis, C.P., Bruner, R.H., Morita, O., Tamaki, Y. and Suzuki, H. A 24- Month Dietary Carcinogenicity Study of DAG (Diacylglycerol) in Mice. Society of Toxicology 43rd Annual Meeting 2004. (Abstract #1026)
Chengelis, C.P., Kirkpatrick, J.B., Bruner, R.H., Morita, O., Tamaki, Y. and Suzuki, H. A 24- Month Carcinogenicity Study of DAG (Diacylglycerol) in Rats with Dietary Optimization. Society of Toxicology 43rd Annual Meeting 2004. (Abstract #1028)
O’Neill, T.P., Chengelis, C.P., Haley, S.C., and Piccirillo, V.J. Validation of the IL 682 co- oximeter for Evaluation of Methemoglobin in the Sprague-Dawley rat. Society of Toxicology 42nd Annual Meeting 2003. (Abstract #154)
Harriman, J.F., Padgett, E.L., Kirkpatrick, D.T., Haas, M.C., Wilkinson, J.T., and Chengelis, C.P. Caloric Restriction Reduces Body Fat, Lean Body Mass, and Palpable Masses While Increasing the 24-month Survival Rate in Sprague-Dawley Rats. Society of Toxicology 42nd Annual meeting 2003. (Abstract #1024)
Chengelis, C.P., Kirkpatrick, J.B., Marit, G.B., Morita, O., Tamaki, Y., and Suzuki, H. Chronic Dietary Toxicity Study of DAG (Diacylglycerol) in Beagle Dogs. Society of Toxicology 42nd Annual meeting 2003. (Abstract #1233)
Schaefer, G.J., Kirkpatrick, D.T., Holson, J.F., Chengelis, C.P., Regan, K.S., and Piccirillo, V.J. A Six-Week Inhalation Neurotoxicity Study of Methylbromide in Dogs. Society of Toxicology 42nd Annual meeting 2003. (Abstract #1476)
Wilkinson, J.T., Padgett, E.L., Kirkpatrick, D.T., Harriman, J.F., Haas, M.C., and Chengelis, C.P. Restriction Reduces Body Fat, Lean Body Mass, and Palpable Masses While Increasing the 24- month Survival Rate in Sprague-Dawley Rats. The Journal of Toxicological Sciences, 72, 211, Abstract S-1. Society of Toxicology 42nd Annual Meeting 2003.
Beck, M.J., Gleason, T.R., Wally, C.S., Chengelis, C.P., Stump, D.G., and Nemec, M.D. Continuous Infusion as a Route of Administration in Embryo/Fetal Development Studies in the Rabbit. Society of Toxicology 42nd Annual Meeting 2003. (Abstract #1586)
Knapp, J.F., Stump, D.G., Varsho, B.J., Nemec, M.D., Holson, J.F. and Chengelis, C.P. (2003) The Journal of Toxicological Sciences, 28, 366, Abstract P-155. Validation of the Hershberger Assay in Peripubertal Orchidoepididyectomized Rats.
Padgett, E.L., Chengelis, C.P., Rhodes, K.K., Holbrook, D.L., Haas, M.C., Lehman, J.L., Bell, C.R. and Nemec, M.D. (2002) Postpartum Developmental Reference Data from Beagle Dogs over Four Defined Pediatric Stages. Toxicologist, Volume 61, 2002. (Abstract #1158)
Stump, D.G., Nemec, M.D., Wally, C.S., Chengelis, C.P., (2002) Embryo/Fetal Developmental Toxicity Studies in Dogs Via Intraveneous Jugular Vein Infusion. The Journal of Toxicological Sciences, Vol. 27, No.4.
Chengelis, C.P., Padgett, E.L., Rhodes, K.K., Frey, R., Simons, M.L., Schaefer, G.J., and Nemec, M.D. (2002) Performance Validation and Demonstration of the Sensitivity to Detect Drug Induced Alterations using a Locomotor Activity System for Large Animals. Toxicologist, Volume 61, 2002. (Abstract #1287)
O’Neill, T.P., Bu, W., Chengelis, C.P., Myers, N., McCarty, J.D., Stetson, P.L., and Sved, D. (2002) Simultaneous Determination of Six Urinary Porphyrins in the Untreated Beagle Dog using Liquid Chromatography - Tandem Mass Spectrometry. Toxicologist, Volume 61, 2002. (Abstract #1724)
Smith, K.J., Wilkinson, J.T., Lake-Bruse, K.D., Schaefer, G.J. and Chengelis, C.P. Pulmonary and Telemetry Cardiovascular Assessment of an Escalating Dose of d-amphetamine sulfate in Rats. Safety Pharmacology Society 2nd Annual Meeting 2002. (Abstract #25)
Schaefer, G.J., Wilkinson, J.T., and Chengelis, C.P. (2001) A Comparison of Heart Rate and Blood Pressure Changes in Dogs and Rats Produced by the Acute Oral Administration of Isoproterenol and Propranolol. Society of Toxicology, Volume 60, Number 1, 2001.
Ivens, I., Leibrandt, M., Sandberg, J., Caputo, F., and Chengelis, C. (2000) Evaluation of Angiozyme, A Ribozyme in 28-Day Toxicity studies in Monkeys and Mice. Presented at the Annual Meeting of the Society of Toxicology, 2000 (Abstract # 1861)
Chengelis, C.P. (2000) Functional Observational Batteries on the Dog. Invited presentation at Safety Evaluation Forum at Tanimoto Gakkou (Nagawa, Nagano, Japan)
Chengelis, C., Elingbam, C., Butt, M., and Maccecchini, M (1999) Subchronic Toxic and Neurotoxic effects of ACPC (1-aminocyclopropane) in Rats. Presented at the Annual Meeting of the Society of Toxicology, 1999 (Abstract # 1695)
Sved, D., Chengelis, C., and Maccecchini, M (1999) Toxicokinetics of ACPC (1- aminocyclopropane) in Rats and Primates. Presented at the 9th North American ISSX Meeting, 1999 (Abstract # 290)
Gleason, T., Chengelis, C., Lindström, P., and Campbell, J. (1999) A 24-Hour Continuous Infusion Study of Bivalirudin in the Rat. Presented at the Annual Meeting of the American College of Toxicology, 1999.
Elangbam, C.S., C.P. Chengelis, K.S. Regan, L.E. Myers and L.J. Watson. (1998). Differences in cell proliferation responses between F344 and Sprague-Dawley rats treated with dichlorobenzene: bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) immunolabeling methods.
Elangbam, C.S., C.P. Chengelis, G.R. Kiplinger, D.J. Naas, J.F. Holson, J.L. Schardein, J.J.W. Mertens, C.B. Jackson, L. Myers and L. Watson. 1,4-Dichlorobenzene-Induced Renal Epithelial Proliferation: Anti-Bromodeoxyuridine and Anti-Proliferating Nuclear Cell Antigen Immunohistochemical and Histopathologic Evaluations, Toxicologic Pathology, Volume 26, Number 1, Page 166, 1998.
Chengelis, C., K. Miller, K. Regan and R.B. Jaeger. Regional Brain Cholinesterase Determinations in the Beagle Dog. Presented at the Annual Meeting of the American College of Toxicology, 1998.
Intravenous Toxicity of BCX-34 in Rats. C.P. Chengelis, J.W. Mertens, C.S. Elangbam and G.R. Walsh. Presented at the Annual Meeting of the American College of Toxicology, 1997.
Knapp, J., T. Gleason, M. Nemec and C.P. Chengelis. A Continuos IV Infusion Embryo/Fetal Development (Method Validation) Study in Rats. Presented at the Annual Meeting of the Society of Toxicology, 1997.
Chengelis, C., "Catecholamine Sensitivity of the Dog Heart". Presented at the NAS/NRC/COT Workshop on The Toxicity of Alternatives to Chlorofluorocarbons held in Irvine, CA, March 7 and 8, 1996. Summarized (1997) by R. Snyder, K. Bakshi and B. Wagner in Abstracts of the Workshop on Toxicity of Alternatives to Chlorofluorocarbons Inhalation Toxicology 9; 775-910.
Pharmacokinetics Metabolism and Tissue Distribution of [14C]-BCX-34 in the rat following intravenous administration. C.P. Chengelis, D.W. Sved and G.M. Walsh. ISSX Proceeding (7th North American Meeting) pp 282, 1996.
Validation and Use of a Computerized ECG System for Collecting, Printing, and Archiving of Electrocardiograms. T. Kern and T. Smith (Introduction by C.P. Chengelis) Presented at the Annual Meeting of the American College of Toxicology, 1996.
Chengelis, C., Naas, D., Nemec, M. and Walters, G. "The Toxicology Evaluation of a Halon Replacement", presented at the Halon Alternatives Workshop Sponsored by NMERI held in Albuquerque, May, 1995.
Boyd, B., Chengelis, C., Cherkofsky, S. and Sved, D.W. "Plasma and Cerebrospinal Fluid (CSF) Pharmacokinetics of 14C-ACPC (Aminocyclopropane-1-carboxylic Acid) in Beagle Dogs", presented at the International Congress of Toxicology, July, 1995.
Mertens, J., Naas, D., Severs, L. Chengelis, C. and Biesemeier, J. "Cardiac Sensitizing Properties of 1,1,1,2,3,3,3-Heptafluoropropane (HFC-227ea, FM-200)", Poster presented at the Annual Meeting of the American College of Toxicology, November, 1995.
Chengelis, C., "Current Methods in Assessing Cardiac Sensitization", Symposium Presentation at the Annual Meeting of the American College of Toxicology, November, 1995.
Lack of Anthracycline Cardiotoxicity associated with N-(2-chloroethyl) nitrosoureidoduanorubicin (AD-312). M. Israel and C.P. Chengelis. Presented at the 1994 Meeting of the American Association of Cancer Research.
A Methods Development and Validation Study for Continuous Infusion of Beagle Dogs. G.R. Kiplinger, D.J. Naas, T.R. Gleason and C.P. Chengelis. Presented at the 1993 Meeting of the American College of Toxicology and published in the J. Amer. Coll. Tox 13, 1994.
A Screen for Antrhacycline Cardiomyopathy in the Mouse (the Bertazzoli Model). A. Appleman, D.J. Naas, R. Dahlgren, C.P. Chengelis and M. Israel. Presented at the 1993 Meeting of the American College of Toxicology and published in the J. Amer. Coll. Toxicol., 13, 1994.
Cardiac Sensitatizing Properties of Bromodifluorormethane (BDFM), C.P. Chengelis, D.J. Naas, L.W. Severs and J. Biesisemeier. Presented at the 1992 meeting of American College of Toxicology and published in the Amer. Coll. Tox. 12, 1993.
Absence of N-Trifluoroacetyladriamycin-14-Valarate (AD-32) Toxicity Following Intraperitoneal Injection in Rats. M. Israel, C.P. Chengelis, D.J. Naas and T.W. Sweatman. Presented at the 1993 meeting of The American Association of Cancer Research.
Mechanism Studies on the Nongenotoxic Carcinogen, Bemitradine. (SC-33643). S. Gad, E. Burton, C.P. Chengelis, S. Levin, C. Piper, Y. Oshiro and D. Semler. Toxicologist 14:330, 1991.
Differences in Acute Toxicity of 6, 7, 8-Trifluoro-1,4-Dihydro-4-Oxoquinoline analogs. S. Gad, C. Chengelis, R. Coyne and D. Naas. Presented at the 1990 Society of Toxicology Meeting,
Subchronic Toxicity SC-39026, an Elastase Inhibitor, in Rats. C.P. Chengelis, S. Levin and C. Cook. Toxicologist 10:1126, 1990.
The role of Epinephrine in Bemitradine Related Adrenal and Cardiac Damage. C. P. Chengelis, S. Gad, S. Levin and A. Costello. Presented at the American College of Toxicology Meeting, October 29-31, 1990.
Health Hazard Assessment and Management in Research and Manufacturing Facilities for the Pharmaceutical Industry. R. Coyne, S. Gad and C. P. Chengelis. Presented by R. Coyne at the American Industrial Hygiene Conference, 1989.
Validation Study for a Guinea Pig Host Resistance Assay. A. Costello, S. Gad, and C. P. Chengelis. Prepared for presentation at the Greater Chicago Chapter of ASPET Annual Meeting, 1989.
Acute Dermal Toxicity of SC-39026, A Leukocyte Elastase Inhibitor. S. Gad and C. P. Chengelis (Searle), and J. Siglin (Springborn). Presented locally at the spring meeting of the Midwest Regional Chapter, Society of Toxicology, 1989.
Metabolism of Bemitradine, an Antihypertensive Diuretic Agent, in the Rat. E. Burton, C.P. Chengelis, G. Walsh, D. Messing, J. Hribar and S. Levin. Presented (by E. Burton) at the Third European Symposium on Foreign Compound Metabolism, 1989.
Acute Dermal Toxicity of 2-Chloro-4-(1-Hydroxyoctadecyl) Benzoic Acid (SC- 39026), A Leukocyte Elastase Inhibitor. S. Gad, C. Chengelis and J. Siglin. Presented at the American College of Toxicology Meeting, October 30 - November 1, 1989. (Revision of abstract 25 above).
Potential Applications for Species Not Commonly Used in General Toxicity Studies. C.P. Chengelis. Invited lecture presented at the symposium on Models for Experimentation in Toxicology Symposium at the American College of Toxicology Meeting, October 30-November 1, 1989.
Cardiovascular Lesions in Rats Associated with Bemitradine, and Experimental Diuretic Antihypertensive Agent. S. Levin and C. P. Chengelis. Presented by S. Levin the 39th Annual Meeting of the American College of Veterinary Pathologists, 1988.
Acute Toxicity of 2-Methylpiperazine. D. Naas and C. P. Chengelis. Toxicologist 9:107, 1989. Bemitradine Induced Cardiotoxicity in Rats. C. P. Chengelis, S. C. Gad, S. Levin, E. Burton and V. Mallory. Toxicologist 9:278, 1989.
Comparative Acute Oral and Dermal Toxicity of 5-Acetyl-salicylamide and 5- Bromoacetylsalicylamide. D. Rodwell, J. Siglin and C. P. Chengelis. Toxicologist 9:163, 1989.
Nephrotoxicity of D- and L-Arginine in Rats. J. M. Andress, C. P. Chengelis, S. C. Gad, C. D. Port and M. S. Tegtmeyer. Toxicologist 8:133, 1988. (Presented a second time at the meeting of the MRC/SOT held 5/16/88).
Correlation of ECG Changes, CPK Levels, and Bemitradine-Induced Myocardial Lesions. A. Costello, S. Levin, G. Walsh, O. Suleymanov and C. P. Chengelis. Presented at the MRC/SOT symposium, May 1988.
"Chronic Toxicity of Bemitradine: Gavage vs. Dietary Admix" delivered on May 17, 1988 at the Spring Meeting of the Drug Safety Subsection - Eastern Region - of the Pharmaceutical Manufacturers Association, May 1988.
Chronic Toxicity of Bemitradine in Rats. C. P. Chengelis, S. Gad and S. Levin. Presented at the American College of Toxicology Meeting, 1988.
A Comparison of Protection Against ANIT-Induced Hepatotoxicity Offered by an E1 and E2 Prostaglandin. C. P. Chengelis, D. Dodd and T. Dennis. Toxicologist 7:57, 1987.
Age and Sex Related Changes in the Hepatic Microsomal Mixed Function Oxidase(s) (MFO) in Rats. C. P. Chengelis, T. Dennis and F. Kotsonis. Presented at the joint ISSX/SOT Symposium, 1987.
Age and Sex Related Changes in Hepatic Epoxide Hydrolase and Enzymes of Conjugation in the Rat. C. P. Chengelis, T. Dennis, and F. Kotsonis. Presented at the joint ISSX/SOT Symposium, 1987.
Stereospecificity of Lysine Nephrotoxicity in Rats. J. A. Andress, C.D. Port, C. P. Chengelis and F. Kotsonis. Toxicologist 6:46, 1986.
Chronic Toxicity of Bromovinyldeoxyuridine (BVDU) in the Beagle Dog. C. P. Chengelis, C. Port and B. Dickie. Toxicologist 6:180, 1986.
Selective Hepatoprotection by 16,16-Dimethyl-PGE2. C. P. Chengelis, D. Dodd and T. Dennis. Pharmacologist 28:146, 1986.
"Toxicity of the Blood" delivered on April 24, 1985 to the graduate level Toxicology class at the University of Illinois, Health Science Campus.
Testicular Toxicity of a Novel 1, 4-Benzodiazepine in the Dog. C. P. Chengelis, D. C. Dodd and F. N. Kotsonis. Pharmacologist 27:199, 1985.
Mechanism of Thyroid Changes Induced by SC-37211 in the Male Rat. C. P. Chengelis, S. Levin, P. Comer and F. Kotsonis. Toxicologist 4:171, 1984.
"Assessment and Prevention of Acute Drug-Induced Hepatic Damage" delivered on April 5, 1984 at the Spring Meeting of the Drug Safety Subsection - Western Region of the Pharmaceutical Manufacturers Association.
The Effects of Zinc Pretreatment on Acetaminophen Hepatotoxicity in Mice. C. P. Chengelis, J. R. Means, D. C. Dodd and F. N. Kotsonis. Pharmacologist 25:225, 1983.
Assessment of D-Penicillamine Nephrotoxicity in Rats. C. P. Chengelis, D. Dodd, F. Kotsonis, and F. Kohn, Pharmacologist 24:189, 1982.
Carbon Disulfide and Carbonyl Sulfide Metabolism by Isolated Hepatocytes. C. P. Chengelis and R. A. Neal, Toxicol. Appl. Pharmacol. 48:11, 1979.
Mechanism of Ethanol-Drug Interactions in Rat Hepatocytes. C. P. Chengelis, Fed. Proceed. 37:318, 1978.